PhoenixBio Co., Ltd. provides contract testing services for medical product development in Japan, the United States, and internationally. The company offers PXB-mouse, a chimeric mouse with a humanized liver used in drug development experiments; and PXB-cells, human hepatocytes for in vitro studies and experiments, as well as HBV study services. Its products are used in gene therapeutics, MASH/MAFLD, viral hepatitis, DMPK/toxicity, and custom transplantations applications. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Frequently asked questions
What sector does PhoenixBio Co Ltd (6190) operate in?
PhoenixBio Co Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is PhoenixBio Co Ltd (6190) current stock price?
As of the latest data, PhoenixBio Co Ltd stock price is ¥352, with a previous close of ¥352.
What is PhoenixBio Co Ltd (6190) current market capitalization?
PhoenixBio Co Ltd market cap is approximately 1.43 billion.
What is PhoenixBio Co Ltd (6190) Earnings Per Share (EPS)?
The trailing EPS is ¥31.
What is PhoenixBio Co Ltd (6190) Price-to-Earnings (P/E) ratio?
PhoenixBio Co Ltd current P/E ratio is 11.44.
What is PhoenixBio Co Ltd (6190) EBITDA?
PhoenixBio Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 23.43 million.
Does PhoenixBio Co Ltd (6190) pay dividends?
No. PhoenixBio Co Ltd does not pay a dividend.
What is PhoenixBio Co Ltd (6190) beta (volatility) score?
PhoenixBio Co Ltd has a beta of 0.370, indicating lower volatility than the overall market.
